Bempedoic Acid: How It Lowers Cholesterol and How It Compares With Statins

Cholesterol management has evolved beyond a single pathway or medication. Many patients benefit from statins. Others need alternatives because of side effects, incomplete response, or specific risk profiles. Bempedoic acid fills an important gap in this broader strategy.

This article explains how bempedoic acid works at a molecular level. It then compares its effects, benefits, and limitations with statins. As noted below, its value lies in precision targeting within the cholesterol synthesis pathway.

Why Another Cholesterol-Lowering Medication Exists

LDL cholesterol remains a major driver of atherosclerotic cardiovascular disease. Lowering LDL reduces heart attack and stroke risk across populations. Yet not all patients tolerate statins well, and not all achieve target LDL levels on statins alone.

Some patients report muscle symptoms. Others prefer nonstatin options. Many sit in between and need combination therapy. A thoughtful and balanced approach considers all of these realities.

Bempedoic acid was developed to address these exact gaps.

The Cholesterol Production Pathway in Simple Terms

The liver produces cholesterol through a multi-step biochemical pathway. Each step relies on a specific enzyme. Blocking different enzymes leads to different clinical effects.

In simplified form:

• Citrate exits the mitochondria.
• ATP citrate lyase converts citrate into acetyl-CoA.
• Acetyl-CoA feeds cholesterol synthesis.
• HMG-CoA reductase performs a later, rate-limiting step.

Statins block HMG-CoA reductase. Bempedoic acid blocks ATP citrate lyase, one step earlier. That distinction explains most of the clinical differences.

How Bempedoic Acid Works Mechanistically

Bempedoic acid is an oral medication taken once daily. It acts inside liver cells and nowhere else in the body.

After absorption, the drug requires activation. An enzyme called ACSVL1 converts bempedoic acid into its active form. This enzyme exists primarily in the liver. Skeletal muscle lacks this enzyme.

Once activated, bempedoic acid inhibits ATP citrate lyase. This reduces the pool of acetyl-CoA available for cholesterol synthesis. As hepatic cholesterol production falls, the liver compensates.

• The liver increases LDL receptor expression.
• More LDL particles get pulled out of the bloodstream.
• Blood LDL cholesterol levels decline.

This indirect mechanism mirrors the final effect of statins but through a different entry point.

Key Mechanistic Features

• Acts upstream of statins in the cholesterol pathway
• Works only in the liver
• Does not activate in muscle tissue
• Lowers LDL by increasing LDL receptor clearance

This liver-selective activation defines its clinical niche.

LDL Reduction You Can Expect

On average, bempedoic acid lowers LDL cholesterol by 15–25%. The effect depends on baseline LDL levels and background therapy.

When combined with ezetimibe, LDL reductions approach 35–40%. When added to statins, the effect remains additive. This predictable response makes it useful for stepwise intensification.

How Statins Work, Briefly Revisited

Statins inhibit HMG-CoA reductase. This enzyme controls the rate-limiting step of cholesterol synthesis. Blocking it strongly suppresses hepatic cholesterol production.

As a result:

• LDL receptors increase
• LDL clearance rises
• LDL drops by 30–60%, depending on dose and statin potency

Statins remain foundational because of their potency and outcome data. However, statins act in both liver and muscle tissue. This explains why muscle-related symptoms can occur in some patients.

Bempedoic Acid vs Statins: A Practical Comparison

Feature	Bempedoic Acid	Statins
Primary enzyme blocked	ATP citrate lyase	HMG-CoA reductase
Site of activation	Liver only	Liver and muscle
Typical LDL reduction	15–25%	30–60%
Muscle symptoms	Rare	Dose-dependent
Unique safety risk	Uric acid elevation (Gout)	Muscle pain / Diabetes risk
Oral dosing	Once daily	Once daily
Best use	Statin intolerance or add-on	First-line therapy

This comparison highlights complementarity, not competition.

1. Why Muscle Symptoms Differ

Muscle symptoms remain the most common reason patients discontinue statins. The mechanism involves mitochondrial effects, altered energy metabolism, and individual susceptibility.

Bempedoic acid avoids this pathway entirely. Because muscle cells cannot activate the drug, they never experience enzyme inhibition. This explains the low incidence of muscle-related complaints. For patients with prior statin intolerance, this difference often matters greatly.

2. Important Safety Note: Uric Acid and Gout

While bempedoic acid avoids muscle toxicity, it has a distinct side effect profile regarding the kidneys. It can increase blood uric acid levels, which may trigger gout, particularly in patients with a history of the condition. Rarely, it has been associated with tendon rupture. Simple monitoring of uric acid levels allows us to use this medication safely.

3. Inflammation and hs-CRP Reduction

Beyond LDL lowering, bempedoic acid modestly reduces hs-CRP. This marker reflects systemic inflammation and vascular risk.

The reduction likely reflects upstream metabolic effects within the liver. While not its primary purpose, this anti-inflammatory signal adds to its broader context. Statins also lower hs-CRP, often more strongly. Still, bempedoic acid provides partial overlap without muscle exposure.

4. Cardiovascular Outcomes Context

Large outcome trials show that LDL lowering, regardless of mechanism, reduces cardiovascular events. Bempedoic acid fits this paradigm.

Patients unable to tolerate statins still benefit from LDL reduction. Those already on statins may benefit from incremental lowering. This aligns with a common-sense approach rather than an all-or-nothing framework.

Patient Scenarios Where Bempedoic Acid Fits Well

• Case 1 — Statin Muscle Intolerance: A 58 year old man stops multiple statins due to reproducible muscle pain. Bempedoic acid lowers LDL by 22% without symptoms.
• Case 2 — Partial Statin Response: A 64 year old woman on moderate statin therapy remains above LDL goals. Adding bempedoic acid achieves target LDL without dose escalation.
• Case 3 — Preference for Oral Nonstatin Therapy: A 51 year old patient declines injectables. Bempedoic acid offers an oral alternative within a comprehensive plan.
• Case 4 — Elevated hs-CRP and LDL: A patient with metabolic risk benefits from modest LDL and inflammatory marker reduction together.
• Case 5 — Combination Strategy: Bempedoic acid plus ezetimibe provides meaningful LDL lowering without statin re-challenge.

These examples show flexibility rather than replacement.

How It Fits Into a Broader Cholesterol Strategy

Modern lipid care rarely relies on one medication alone. Genetics, insulin resistance, inflammation, and lifestyle all interact.

Bempedoic acid works best when:

• Diet and metabolic factors receive attention
• ApoB and non-HDL cholesterol guide decisions
• Combination therapy gets used thoughtfully
• The broader context drives choices

This layered thinking prevents oversimplification.

Takeaway: Precision Matters in Cholesterol Care

Bempedoic acid lowers LDL cholesterol by targeting ATP citrate lyase in the liver. Its liver-specific activation avoids muscle exposure. This explains its tolerability profile.

Statins remain foundational because of potency and long-term data. Bempedoic acid complements them or substitutes when needed. A balanced viewpoint recognizes that both serve important roles.

At our practice in Montgomery County, Maryland, and through virtual care, we use individualized, holistic strategies to match the right cholesterol therapy to each patient’s biology, preferences, and long-term cardiovascular risk.